GMED GLOBUS MEDICAL INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1237831 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.4%
TTM net income YoY31.6%
TTM EPS YoY31.4%
Revenue 3-yr CAGR36.8%
Net income 3-yr CAGR52.3%
Margins
Gross margin69.1%
Operating margin21.6%
Net margin17.8%
FCF margin24.4%
EBITDA margin28.7%
Returns
ROE12.1%
ROA10.5%
ROIC (approx.)12.9%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets13.2%
Debt / equity0.00x
Current ratio4.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.66x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $763.72M | $789.61M | $759.85M | $826.42M | $769.05M | $745.34M | $598.12M | $657.29M |
| Cost of revenue | $232.92M | $241.44M | $234.07M | $261.11M | $252.53M | $248.76M | $195.40M | $263.44M |
| Gross profit | $530.80M | $548.17M | $525.79M | $565.31M | $516.51M | $496.58M | $402.72M | $393.86M |
| R&D expense | $34.53M | $36.32M | $36.51M | $36.16M | $38.07M | $39.95M | $33.06M | $33.41M |
| SG&A expense | $288.47M | $286.82M | $297.77M | $318.48M | $313.60M | $303.62M | $242.80M | $253.17M |
| Operating income | $177.55M | $182.43M | $150.39M | $169.34M | $137.36M | $76.11M | $97.00M | $60.27M |
| Pretax income | $183.27M | $189.82M | $157.07M | $169.23M | $143.99M | $188.17M | $103.67M | $24.67M |
| Income tax | $42.10M | $38.25M | $32.77M | $28.64M | $25.03M | -$14.67M | $28.21M | -$1.84M |
| Net income | $141.17M | $151.57M | $124.30M | $140.59M | $118.97M | $202.85M | $75.46M | $26.50M |
| EBITDA | $218.91M | $222.96M | $220.24M | $238.82M | $178.65M | $116.55M | $162.66M | $127.87M |
| EPS (basic) | 1.05 | 1.12 | 0.92 | — | 0.88 | 1.50 | 0.55 | — |
| EPS (diluted) | 1.04 | 1.10 | 0.90 | — | 0.88 | 1.49 | 0.54 | — |
| Weighted avg. shares (diluted) | 136.02M | 137.38M | 138.19M | — | 135.39M | 136.50M | 139.77M | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | $1.46M | $693,000 | $1.68M | $815,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $441.27M | $507.75M | $560.95M | $526.16M | $371.77M | $229.45M | $461.27M | $784.44M |
| Short-term investments | $76.16M | $87.40M | $68.90M | $31.09M | $18.75M | — | — | $105.62M |
| Receivables | $675.30M | $692.18M | $686.43M | $678.94M | $619.12M | $611.57M | $535.09M | $557.70M |
| Inventory | $824.14M | $810.90M | $772.60M | $759.28M | $771.54M | $772.13M | $663.60M | $659.23M |
| Current assets | $2.18B | $2.22B | $2.20B | $2.13B | $1.92B | $1.73B | $1.71B | $2.18B |
| PP&E, net | $532.76M | $533.53M | $557.14M | $564.45M | $577.79M | $587.50M | $556.50M | $561.91M |
| Goodwill | $1.45B | $1.44B | $1.44B | $1.44B | $1.43B | $1.43B | $1.43B | $1.43B |
| Intangibles | $667.47M | $692.62M | $720.85M | $745.06M | $773.90M | $796.37M | $771.69M | $795.12M |
| Total assets | $5.53B | $5.49B | $5.44B | $5.30B | $5.10B | $4.96B | $4.71B | $5.25B |
| Current liabilities | $507.94M | $479.35M | $482.46M | $498.50M | $465.96M | $424.66M | $384.70M | $855.91M |
| Total liabilities | $731.94M | $719.65M | $707.24M | $729.51M | $696.82M | $665.41M | $623.08M | $1.07B |
| Shareholders' equity | $4.80B | $4.77B | $4.73B | $4.57B | $4.40B | $4.30B | $4.09B | $4.18B |
| Cash flow statement | ||||||||
| Operating cash flow | $265.23M | $209.74M | $202.36M | $248.59M | $249.69M | $77.86M | $177.30M | $210.34M |
| Capital expenditure | $40.39M | $33.17M | $39.62M | $46.20M | $35.82M | $46.56M | $36.10M | $17.11M |
| Free cash flow | $224.84M | $176.57M | $162.75M | $202.39M | $213.88M | $31.30M | $141.20M | $193.23M |
| Investing cash flow | -$155.90M | -$129.05M | -$182.67M | -$111.45M | -$75.84M | -$299.11M | $131.38M | -$104.12M |
| Financing cash flow | -$130.76M | -$134.50M | $18.20M | $13.21M | -$32.04M | -$24.94M | -$635.40M | $59.73M |
| Depreciation & amortization | $41.36M | $40.52M | $69.86M | $69.48M | $41.28M | $40.44M | $65.65M | $67.59M |
| Stock-based compensation | $11.74M | $13.38M | $12.62M | $11.42M | $11.54M | $13.62M | $13.21M | $11.91M |
| Share buybacks | $142.94M | $136.06M | $0 | $45.00M | $40.00M | $25.00M | $190.45M | $1.00M |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.